Menu
Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on ...
- First patient enrolled in RE-COVERY DVT/PE™
- Involving 14,000 patients worldwide, the study will collect real-world data on reducing the risk of DVT and PE with Pradaxa®1
(BUSINESS WIRE)-- Boehringer Ingelheim today announces the enrollment of the first patient in RE-COVERY DVT/PE™, a global observational study on the management of blood clots in the legs (deep vein thrombosis, DVT) and in the lungs (pulmonary embolism, PE). The new study will provide insights into how patients with DVT and PE are being treated in real-world clinical practice, and will add to the growing body of data on the safety and effectiveness of Pradaxa® (dabigatran etexilate) compared to warfarin. ...
Source : http://me-newswire.net//news/17407/en...
Dans la même rubrique :
Mercredi 19 Novembre 2025 - 15:00 Algérie : la BAD salue les grands chantiers lancés |
Mercredi 5 Novembre 2025 - 18:21 Tchad : Star Oil Tchad et Airtel Money s'allient pour accélérer l'inclusion financière |
Mardi 28 Octobre 2025 - 19:45 Tchad : Atelier de Formation sur l'Utilisation des Images par le Volet des Standards des Ménages (EHCVM) |
